News Feature | Published:

Hepatitis C: move over interferon

Nature Biotechnology volume 29, pages 963966 (2011) | Download Citation

Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral combination antiviral regimens without interferon α. But the virus is a long way from vanquished. Ken Garber investigates.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nat. Biotechnol. 29, 993–1003. (2011).

  2. 2.

    et al. J. Hepatol. 54, Suppl. 1, S536, abstract 1356 (2011).

  3. 3.

    et al. AASLD annual meeting abstract LB-5 (2011).

  4. 4.

    Nat. Biotechnol. 25, 1379–1381 (2007).

  5. 5.

    et al. Nature 465, 96–100 (2010).

  6. 6.

    et al. Nature 435, 374–379 (2005).

  7. 7.

    et al. AASLD annual meeting abstract LB-4 (2011).

  8. 8.

    et al. Nature 461, 399–401 (2009).

  9. 9.

    et al. Nature 461, 798–801 (2009).

  10. 10.

    & Nature 465, 42–44 (2010).

Download references

Author information

Affiliations

  1. Ann Arbor, Michigan

    • Ken Garber

Authors

  1. Search for Ken Garber in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2031

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing